A Double-Blind, Placebo-Controlled Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)
Phase of Trial: Phase IV
Latest Information Update: 16 Aug 2019
Price : $35 *
At a glance
- Drugs Brexpiprazole (Primary) ; Ketamine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- 13 Aug 2019 Status changed from active, no longer recruiting to completed.
- 07 Feb 2019 Planned End Date changed from 31 Jan 2019 to 30 Apr 2019.
- 07 Feb 2019 Planned primary completion date changed from 31 Dec 2018 to 31 Mar 2019.